Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in Scrip
Executive Summary
Pfizer Inc. released positive Phase III data from two induction trials testing its oral Janus kinase inhibitor Xeljanz (tofacitinib) in patients with the inflammatory bowel disease ulcerative colitis, but the company will await the results of another Phase III maintenance study before filing for an indication expansion.